[Expression Levels of JARID1B, Hes1 and MMP-9 Genes in CML Patients Treated with Imatinib Mesylate].

Publisher: Zhongguo shi yan xue za zhi she Country of Publication: China NLM ID: 101084424 Publication Model: Print Cited Medium: Print ISSN: 1009-2137 (Print) Linking ISSN: 10092137 NLM ISO Abbreviation: Zhongguo Shi Yan Xue Ye Xue Za Zhi Subsets: MEDLINE

Original Publication: Beijing : Zhongguo shi yan xue za zhi she,

Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy; Antineoplastic Agents/*therapeutic use ; Imatinib Mesylate/*therapeutic use; Humans ; Jumonji Domain-Containing Histone Demethylases ; Matrix Metalloproteinase 9 ; Nuclear Proteins ; Repressor Proteins ; Transcription Factor HES-1

Objective: To explore the relationship between the expression levels of JARID1B,Hes1 and MMP-9 genes and the stages of chronic myelogenous leukemia(CML) and the curative effect of imatinib mesylate (IM).
Methods: Peripheral blood samples of 15 cases of CML in chronic phase and 10 cases of CML in progressive phase were collected from the Hematology Department of Taihe Hospital affiliated to Hubei University of Medicine and 15 cases of healthy people in the Physical Examination Center. CML patients were divided into effective group and ineffective group based on the efficacy after treatment with IM, then real-time PCR was used to detect the expression levels of JARID1B, Hes1 and MMP-9 mRNA, finally, the differences in the level of gene expression and their correlations with CML stages and IM curative efficacy were analysed.
Results: The expression levels of Hes1 and MMP-9 in initially diagnosed patients in chronic and progressive phase without IM treatment were significantly higher than those of health people（P＜0.05）. There was no significant difference in the expression level of JARID1B between chronic phase patients and health people（P＞0.05）, but the expression level of JARID1B in the progressive phase patients was higher than that of health people （P＜0.05）. The expression levels of JARID1B and Hes1 in the IM-effective group were not significantly different from those in the IM-ineffective group (P=0.85,P=0.82）, while the expression level of MMP-9 in the IM-effective group [JP2]was significantly lower than that in the IM-ineffective group（P＜0.05）.
Conclusion: The expression levels of JARID1B Hes1 and MMP-9 relate with the different phase of CML; The expression levels of JARID1B and Hes1 have not significant relationship with IM curative efficacy, the MMP-9 gene expression level relates with IM curative efficacy.

Local Abstract: [Publisher, Chinese] 伊马替尼治疗的慢性髓系白血病患者JARID1B、Hes1和MMP-9基因表达水平差异的研究. [Publisher, Chinese] 探讨JARID1B、Hes1和MMP-9基因表达水平与慢性髓系白血病（chronic myelogenous leukemia，CML）疾病的病程阶段及伊马替尼（imatinib mesylate, IM）疗效的关系. [Publisher, Chinese] 收集湖北医药学院附属太和医院血液科CML患者25例 (慢性期15例、进展期10例)和体检中心正常人15例的外周血标本。按初次确诊为CML患者的病期和服用IM后的疗效分组（有效组和无效组），采用实时定量RT-PCR方法检测JARID1B、Hes1和MMP-9基因mRNA表达水平，分析JARID1B、Hes1和MMP-9基因表达水平差异与疾病阶段及IM疗效的相关性。. [Publisher, Chinese] 初次确诊未服用IM慢性期和进展期CML患者Hes1和MMP-9基因的表达水平明显高于正常人（P＜0.05）；CML患者慢性期JARID1B基因的表达水平与正常人相比无明显差异（P=0.20），进展期患者JARID1B的表达水平明显高于正常人（P＜0.05）；IM治疗有效组JARID1B和Hes1基因的表达水平与无效组相比无明显差异（P=0.85、P=0.82），MMP-9的表达水平有效组明显低于无效组（P＜0.05）. [Publisher, Chinese] JARID1B、Hes1和MMP-9基因的表达水平与CML的不同病程分期有关；JARID1B、Hes1基因表达水平与IM疗效无关，MMP-9基因表达水平与IM疗效有关.

0 (Antineoplastic Agents)
0 (Nuclear Proteins)
0 (Repressor Proteins)
0 (Transcription Factor HES-1)
149348-15-2 (HES1 protein, human)
8A1O1M485B (Imatinib Mesylate)
EC 1.14.11.- (Jumonji Domain-Containing Histone Demethylases)
EC 1.14.11.- (KDM5B protein, human)
EC 3.4.24.35 (MMP9 protein, human)
EC 3.4.24.35 (Matrix Metalloproteinase 9)

Date Created: 20190817 Date Completed: 20190827 Latest Revision: 20190827

20231215

10.19746/j.cnki.issn.1009-2137.2019.04.013

31418359